Nervgen Pharma Corp. · NASDAQ:NGEN
Nervgen Pharma — Investor Presentation (February 2025)
26 slides from Nervgen Pharma's investor presentation, Feb 7, 2025
Slide 1: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself Corporate Presentation February 2025
Slide 2: Financial Disclosure Statement
Financial Disclosure Statement Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disappr
Slide 3: NervGen Highlights
NervGen Highlights Multiple preclinical studies using NVG-291-R Q1 2025 – NVG-300 Q2 2025 – Phase 1b/2a reported improvement preclinical data readout proof-of-concept in axonal repair, in models of ischemic readout in people living plasticity, and motor, stroke, ALS and SCI with chronic SCI sensory
Slide 4: History of NervGen Technology
History of NervGen Technology Phase 1b/2a Trial Jerry Silver, PhD Dr. Silver discovered glial Dr. Silver and Harvard Dr. Silver's team designed a NervGen licensed NVG-291 NervGen initiated a Phase scars contain chondroitin collaborators co-discovered peptide (NVG-291-R) global rights for 1b/2a place
Slide 5: NVG-291-R Improves CNS/PNS Repair in Preclinical Efficacy Models
NVG-291-R Improves CNS/PNS Repair in Preclinical Efficacy Models Enhanced Plasticity, Repair (Axonal, Myelination), and Recovery of Function ACUTE SPINAL CHRONIC SPINAL STROKE MULTIPLE PERIPHERAL NERVE OPTIC NERVE Conditions Modeled CORD INJURY CORD INJURY (Ischemic, SCLEROSIS (EAE) INJURY DEMYELINA
Slide 6: Product Pipeline
Product Pipeline Multiple development opportunities CANDIDATE PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 1b/2a Spinal Cord Injury NVG-291 Ischemic Stroke Ischemic Stroke Amyotrophic Lateral Sclerosis NVG-300* Alzheimer's Disease Multiple Sclerosis 6 *Internally developed
Slide 7: Markets and Opportunity in Nervous System Injury & Disease
Markets and Opportunity in Nervous System Injury & Disease Significant medical costs and morbidity Spinal Cord Injury Ischemic Stroke ALS Multiple Sclerosis Alzheimer’s Disease Incidence* 18,000 ~690,000 ~7,000 10,000 500,000 Prevalence* 291,000 9.4M ~25K-30K ~1M 6.7M Lifetime Cost* $1M-$4M+ $140,00
Slide 8: SCI Demographics & Characteristics
SCI Demographics & Characteristics • Average age: ~43 • Male (78%), female (22%) • Cause: vehicle (38%); fall (33%); violence (15%); sports (8%) • Annual hospitalization (30%): UTI, pneumonia, decubitus ulcers • Duration of hospitalization and rehabilitation: 2 to 3 months • Chance of depression: 25
Slide 9: SCI Facts and Figures
SCI Facts and Figures Incidence and Prevalence Economic Impact Individuals with SCI face a difficult and expensive journey Spinal cord injuries every year through the healthcare system; that journey begins with ~18,000 in the US1 2-3 months in rehabilitation and costs $200,000 or more per patient3
Slide 10: NVG-291-R Promotes Recovery in Acute SCI
NVG-291-R Promotes Recovery in Acute SCI Overview Hindlimb Function T8 compression injury 20 21 = Normal • Treatment start: 1 day post-injury Treatment Period function **** **** **** • Dose: 500 µg/day x 7 weeks ≥14 = fine 15 **** NVG-291-R motor (N=10) movements Results BBB Score 10 *** Occasional
Slide 11: Improved Bladder Function After NVG-291-R in Preclinical Models
Improved Bladder Function After NVG-291-R in Preclinical Models Bladder Dose Response1 1.5 100% Void Frequency (voids / hour) ** * of animals in the two highest dose groups 1.0 Responders had improved bladder (2x SD of vehicle mean) control function 1Animals tested at week 12 post-SCI; graphs show g
Slide 12: NVG-291-R Improves Function in Severe Spinal Cord Injury Model
NVG-291-R Improves Function in Severe Spinal Cord Injury Model Representative of Placebo Group Representative of NVG-291-R Group (Back Legs and Tail Dragging) (Back Legs and Tail Active) Play with solid fill Click here to play video Click here to play video Remarkable and robust repair across multip
Slide 13: NVG-291-R Enables Significant Motor Recovery in Severe SCI Model
NVG-291-R Enables Significant Motor Recovery in Severe SCI Model Representative of Placebo Group Representative of NVG-291 Group Play with solid fill Click here to play video Click here to play video Hind legs are immobile in placebo-treated Significant motor recovery with NVG-291-R: consistent anim
Slide 14: Chronic SCI Preclinical Study
Chronic SCI Preclinical Study Overview Results C2 lateral hemisection model of SCI NVG-291-R promoted recovery in chronic SCI • Treatment start: 12 weeks post-injury • Significant recovery of forelimb locomotor function • Dose: 500 µg/day x 8.5 weeks • Functional improvements persist after treatment
Slide 15: NVG-291 Phase 1 Clinical Trial in Healthy Volunteers
NVG-291 Phase 1 Clinical Trial in Healthy Volunteers Study Design Safety Results Single Dose • Well tolerated across all doses • 37 subjects − Maximum tolerated dose (MTD) not reached • 6 dose levels • No treatment discontinuations • Assessed through Day 8 • No serious/severe adverse events (AE) in
Slide 16: Phase 1b/2a Trial of NVG-291-201 in SCI
Phase 1b/2a Trial of NVG-291-201 in SCI No NVG-291 intervention Over 16 weeks Screening No Placebo intervention • Daily SQ injections (12 weeks) Wk0 Wk4 Wk8 Wk12 Wk16 • Electrophysiological assessments • Clinical assessments • Exercise/training: ~5 days per week Single-center study – Shirley Ryan Ab
Slide 17: Phase 1b/2a Study Inclusion & Exclusion Criteria
Phase 1b/2a Study Inclusion & Exclusion Criteria Key Inclusion Criteria Key Exclusion Criteria Age 18-75 Non-traumatic SCI Traumatic SCI SCI from gunshot or penetrating/stab injury Neurological level of injury C7 or higher Two or more (non-contiguous) spinal cord lesions Motor incomplete with minima
Slide 18: Phase 1b/2a Trial Primary Objective and Co-Primary Endpoints
Phase 1b/2a Trial Primary Objective and Co-Primary Endpoints Primary Objective Ten Muscle Groups Assessed To evaluate the effect of NVG-291 compared to placebo on relative Upper extremity Lower extremity percentage change in corticospinal connectivity to qualifying muscle groups Biceps brachii Quadr
Slide 19: Phase 1b/2a Trial Secondary Endpoints (Clinical)
Phase 1b/2a Trial Secondary Endpoints (Clinical) 01 Change from baseline to Week 12 in 04 Change from baseline to Week 12 in GRASSP 04 version 2 scores 10mWT time Change from baseline to Week 12 in lower 02 Change from baseline to Week 12 in 9-HPT time 05 05 extremity motor scores 03 Change from bas
Slide 20: Additional Patient-Reported Data: Qualitative Review of Subject Experience
Additional Patient-Reported Data: Qualitative Review of Subject Experience Literature Review Reporting Interview Guide Patient Experience Incorporating qualitative semi-structured Qualitative Analysis Analysis subject interviews Plan Exploring subjects’ experiences of potential beneficial treatment
Slide 21: NVG-300, A Proprietary Molecule Diversifying Pipeline and Opportunity for Partnering
NVG-300, A Proprietary Molecule Diversifying Pipeline and Opportunity for Partnering A new proprietary molecule discovered at NervGen Eligible for the BLA development path 01 03 in 2022 Demonstrated favorable pharmaceutical properties Composition of matter IP protection 02 04 (solubility, metabolic
Slide 22: Experienced Leadership Team
Experienced Leadership Team MIKE KELLY, MBA, CHIEF EXECUTIVE OFFICER CHUCK OLSON, DSC, SR. VP, TECHNICAL OPERATIONS Over 30 years of pharmaceutical experience. Formerly President of US Ops for Adapt Pharma, Inc., which developed and commercialized Over 40 years of experience in process development,
Slide 23: Board of Directors
Board of Directors Glenn Ives Chairman Former Partner, Deloitte LLP Harold Punnett, DMD Mike Kelly Adam Rogers, MD Co-Founder Former CEO & Co-Founder, Hemera President & CEO, NervGen Brian Bayley Neil Klompas John Ruffolo Director, Earlston Investments President & CEO, Augurex Founder & Managing Par
Slide 24: Upcoming Milestones
Upcoming Milestones Q1 2025 Initiate dosing in subacute cohort in Phase 1b/2a proof-of- concept in people living with SCI NVG-300 preclinical data readout in models of ischemic stroke and ALS Q2 2025 Phase 1b/2a proof-of-concept readout in people living with chronic SCI 24
Slide 25: Share and Capital Structure
Share and Capital Structure Exchange/Market: Ticker TSX: NGEN.V OTCQB: NGENF Recent Share Price (Feb 7, 2025) CA$2.86 / US$2.02 Shares Outstanding 70.6 million Fully Diluted 93.2 million (~12.5 million options & retention securities, ~10.1 million warrants*) Insider Ownership 21.1% Cash & Cash Equiv
Slide 26: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself www.nervgen.com Certain images in this presentation are sourced from Flaticon All trademarks are the property of their respective Company owners
NervGen Pharma — Investor Presentation (February 2025) on 6ix